Metagenomi to regain full development rights to its wholly-owned base editing and RIGS systems
May 01, 2024 16:00 ET
|
Metagenomi, Inc.
EMERYVILLE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its...
Metagenomi to Present at Upcoming Scientific Meetings
April 08, 2024 08:00 ET
|
Metagenomi, Inc.
- Oral Presentation at World Federation of Hemophilia (WFH) World Congress, April 23, 2024 - Two Posters at American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, May 8...
Metagenomi Reports Business Updates and Full Year 2023 Financial Results
March 27, 2024 09:16 ET
|
Metagenomi, Inc.
Demonstrated nonhuman primate proof of concept in Hemophilia A program; progressing towards Development Candidate nomination by mid-year; 12-month nonhuman primate durability data in 2H 2024 Proof of...
Metagenomi to Participate in the 44th Annual Cowen Healthcare Conference
February 29, 2024 16:30 ET
|
Metagenomi Technologies, LLC
EMERYVILLE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for...
Metagenomi Announces Closing of Initial Public Offering
February 13, 2024 16:35 ET
|
Metagenomi Technologies, LLC
EMERYVILLE, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its...
Metagenomi Announces Pricing of Initial Public Offering
February 08, 2024 22:16 ET
|
Metagenomi Technologies, LLC
EMERYVILLE, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (“Metagenomi”), a precision genetic medicines company committed to developing curative therapeutics for patients...